Meeting
2016 ASCO Annual Meeting
Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non–small cell lung carcinoma (NSCLC): KEYNOTE-189.
Authors
Richard Delmar Hall
University of Virginia, Charlottesville, VA
Richard Delmar Hall , Shirish M. Gadgeel , Edward B. Garon , Emilio Bria , Martin Reck , John Vida , Honghong Zhou , Harry Raftopoulos , Leena Gandhi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02578680
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS9104)
DOI
10.1200/JCO.2016.34.15_suppl.TPS9104
Abstract #
TPS9104
Poster Bd #
424b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
First Author: Martin Reck
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2019 ASCO Annual Meeting
Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.
First Author: Rina Hui